| 发明名称 | Method of treating type 1 diabetes by administering NKp46 polypeptide | ||
| 摘要 | The invention relates to use of the natural cytotoxicity receptor NKp46 for preventing and treating diabetes, including type I diabetes (TID) and type 2 diabetes. In particular, the invention provides compositions comprising a fragment of the extracellular region of NKp46 for preventing the onset and progression of diabetes. | ||
| 申请公布号 | US8980244(B2) | 申请公布日期 | 2015.03.17 |
| 申请号 | US201313862927 | 申请日期 | 2013.04.15 |
| 申请人 | Ben-Gurion University of the Negev Research and Development Authority;Hadasit Medical Research Services and Development Ltd.;Yissum Research Development Company of the Hebrew University of Jerusalem, Ltd. | 发明人 | Mandelboim Ofer;Porgador Angel;Naparstek Yaakov;Gur Chamutal |
| 分类号 | A61K38/17;A61K39/395;C07K16/28;C07K14/705;A61P3/10;A61K39/00;A61K38/00 | 主分类号 | A61K38/17 |
| 代理机构 | Browdy and Neimark, PLLC | 代理人 | Browdy and Neimark, PLLC |
| 主权项 | 1. A method for treating type 1 diabetes, the method comprising administering to a subject in need thereof, a therapeutically effective amount of a composition comprising at least one protein and a pharmaceutically acceptable carrier, wherein the protein comprises a natural cytotoxicity receptor p46 (NKp46) or an isolated fragment of the extracellular region of NKp46, wherein the isolated fragment of the extracellular region of NKp46 comprises the D2 domain, thereby treating type 1 diabetes in the subject. | ||
| 地址 | Beer Sheva IL | ||